Deacons can help you navigate the challenges of doing business in China and advise on practical steps to protect and manage your IP assets and use them to their greatest advantage.
As China continues to encourage foreign investment, taking advantage of the opportunities for doing business in China requires professional advice from someone familiar with the local law, thorough due diligence and a holistic IP strategy and knowledge of cross-border issues. Our team understands the complexities of Chinese contract law and regulations and can provide pragmatic advice on your commercial transactions to ensure effective arrangements, practical protection and predictable contract enforcement.
Deacons’ IP team offers wide-ranging consultation services connected with the effective commercialisation of IP assets in China. In particular, our lawyers have considerable experience of all kinds of China-related commercial advisory work, from IP audits, due diligence, consumer rights and local law compliance, to acquisitions and joint ventures. We also advise on a broad range of transactional IP agreements from assignments, franchising, licences, manufacturing and distribution agreements, to celebrity endorsements and brand collaborations, to R&D, IT and e-commerce agreements. We also regularly advise on the IP aspects of advertising in China, including online marketing campaigns and related agreements.
Advised JAC (a subsidiary of JIC Capital, which is a Chinese state-owned investment company) on the US $1.8 billion acquisition of the RF Power business of NXP. The transaction focused heavily on IP and technology transfer aspects, which amounted to approximately half of the transaction value. This was one of the largest outbound technology deals of 2015.
Assisted Ampleon Netherlands B.V. (a company divested from NXP B.V. and one of the leading providers of RF Power electronics), with the evaluation, negotiation and securing of third party patent licences and cross-licences based on the divested entity provisions of third party licence agreements entered into by NXP.
Advised Winshine Entertainment & Media Holding Company Limited and its wholly-owned subsidiary, Billion Pride on the RMB 100 million formation of a joint venture with Novotide BVI. We handled the due diligence of the related technology for malignant tumour treatment and the preparation and negotiation of the license agreement.
Advised a Boston based biotech company on the establishment of a joint venture for personal genetic testing and stem cell bio banking, including advising on the joint venture documentation, patent and trade mark licensing, exclusive distribution agreement, and whether technology exploration rights can be a capital contribution in Mainland China.
Advised a syndicate of Chinese and Hong Kong investors on establishing a joint venture in the UK and conducting due diligence on patents, software and IPs in relation to robotic technologies applied in minimal invasive surgery and endoscopic surgery.